GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Silo Wellness Inc (XCNQ:SILO) » Definitions » Inventories, Other

Silo Wellness (XCNQ:SILO) Inventories, Other : C$0.00 Mil (As of Jul. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Silo Wellness Inventories, Other?

Other inventories including goods for resale, stocks in transit, consignment stocks, etc. Silo Wellness's other inventories for the quarter that ended in Jul. 2023 was C$0.00 Mil.

Silo Wellness's annual other inventories increased from Oct. 2020 (C$0.01 Mil) to Oct. 2021 (C$0.11 Mil) but then declined from Oct. 2021 (C$0.11 Mil) to Oct. 2022 (C$0.00 Mil).


Silo Wellness Inventories, Other Historical Data

The historical data trend for Silo Wellness's Inventories, Other can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silo Wellness Inventories, Other Chart

Silo Wellness Annual Data
Trend Oct20 Oct21 Oct22
Inventories, Other
0.01 0.11 -

Silo Wellness Quarterly Data
Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23
Inventories, Other Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Silo Wellness Inventories, Other Calculation

Other inventories including goods for resale, stocks in transit, consignment stocks, etc.


Silo Wellness (XCNQ:SILO) Business Description

Traded in Other Exchanges
N/A
Address
200 Consumers Road, Suite 702, Toronto, ON, CAN, M2J 4R4
Silo Wellness Inc operates psychedelic clinics and develops legal functional mushroom consumer products. It is focused on health and wellness by developing and introducing psychedelic medicine to reduce trauma and increase performance by destigmatizing the active compounds in psychedelics and innovating ease of administration and ingestion.
Executives
Michael Hartman Director